STERIS plc (NYSE:STE – Get Free Report) has received an average recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $258.75.
STE has been the subject of several research reports. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research report on Thursday, February 6th. Piper Sandler lifted their target price on STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Finally, Stephens reaffirmed an “overweight” rating and issued a $240.00 target price on shares of STERIS in a research report on Thursday, February 6th.
Check Out Our Latest Report on STE
STERIS Stock Up 2.1 %
STERIS (NYSE:STE – Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. On average, sell-side analysts forecast that STERIS will post 9.08 earnings per share for the current year.
STERIS Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be given a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.00%. The ex-dividend date of this dividend is Thursday, February 20th. STERIS’s dividend payout ratio is presently 48.41%.
Hedge Funds Weigh In On STERIS
Institutional investors and hedge funds have recently made changes to their positions in the stock. Ashton Thomas Securities LLC acquired a new position in shares of STERIS during the third quarter worth about $25,000. Avalon Trust Co acquired a new position in shares of STERIS during the fourth quarter worth about $30,000. Human Investing LLC acquired a new position in shares of STERIS during the fourth quarter worth about $31,000. Anfield Capital Management LLC grew its position in shares of STERIS by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 91 shares in the last quarter. Finally, Central Pacific Bank Trust Division lifted its stake in STERIS by 65.5% during the fourth quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 76 shares during the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.
About STERIS
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Further Reading
- Five stocks we like better than STERIS
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Short Nasdaq: An Easy-to-Follow Guide
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.